A018620 Stock Overview
Engages veterinary medicines, microbial technology, and vaccines business in South Korea and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
WooGene B&G Co., Ltd Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩1,044.00 |
52 Week High | ₩1,590.00 |
52 Week Low | ₩962.00 |
Beta | 0.69 |
11 Month Change | -5.52% |
3 Month Change | -10.85% |
1 Year Change | -21.39% |
33 Year Change | -59.53% |
5 Year Change | -53.29% |
Change since IPO | -50.60% |
Recent News & Updates
Recent updates
Shareholder Returns
A018620 | KR Pharmaceuticals | KR Market | |
---|---|---|---|
7D | 1.9% | 7.5% | -1.9% |
1Y | -21.4% | 17.8% | 0.6% |
Return vs Industry: A018620 underperformed the KR Pharmaceuticals industry which returned 17.8% over the past year.
Return vs Market: A018620 underperformed the KR Market which returned 0.6% over the past year.
Price Volatility
A018620 volatility | |
---|---|
A018620 Average Weekly Movement | 4.0% |
Pharmaceuticals Industry Average Movement | 6.6% |
Market Average Movement | 6.5% |
10% most volatile stocks in KR Market | 12.2% |
10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A018620 has not had significant price volatility in the past 3 months.
Volatility Over Time: A018620's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1977 | 92 | Seokjin Kang | www.woogenebng.com |
WooGene B&G Co., Ltd. engages veterinary medicines, microbial technology, and vaccines business in South Korea and internationally. It offers antibiotic, vaccine, nutrient, anti-inflammation, metabolic stimulant, and iron supplement products for swine, poultry, cattle, aquatic animals, companion animals, and raw materials, as well as operates vaccine research center. The company was formerly known as WooJin Co., Ltd.
WooGene B&G Co., Ltd Fundamentals Summary
A018620 fundamental statistics | |
---|---|
Market cap | ₩30.16b |
Earnings (TTM) | -₩687.55m |
Revenue (TTM) | ₩60.62b |
0.5x
P/S Ratio-43.9x
P/E RatioIs A018620 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A018620 income statement (TTM) | |
---|---|
Revenue | ₩60.62b |
Cost of Revenue | ₩44.35b |
Gross Profit | ₩16.28b |
Other Expenses | ₩16.96b |
Earnings | -₩687.55m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -23.80 |
Gross Margin | 26.85% |
Net Profit Margin | -1.13% |
Debt/Equity Ratio | 41.8% |
How did A018620 perform over the long term?
See historical performance and comparison